Document Detail


New drugs in acute myeloid leukemia.
MedLine Citation:
PMID:  12162909     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The acute myeloid leukemias (AML) are often fatal disorders with a range of clinical, morphologic, cytogenetic, and molecular features and a consequent need for a diverse array of therapies. This need for tailored therapy for subsets of patients with AML is exemplified in those with acute promyelocytic leukemia, the subject of a separate article in this issue (Tallman and Nabhan). Unfortunately, we tend to examine novel agents in patients with very advanced disease, in which prior therapies have inevitably altered the tumor. Of a myriad of possible exciting novel agents, a few, including PS-341, Genasense (Genta, Berkeley Heights, NJ), decitabine, 5-azacytidine, clofarabine, and troxacitabine, are briefly reviewed with an emphasis on their mechanisms of action from a perspective that suggests possible synergistic therapeutic interventions. With the growing appreciation of the pivotal role of angiogenesis in AML, angiogenesis modulators are a good example of a core class of drugs upon which future noncytotoxic combinations may be built. Those agents targeting vascular endothelial growth factor are also briefly reviewed.
Authors:
Francis J Giles
Related Documents :
17223919 - The haematopoietic cell transplantation comorbidity index score is predictive of early ...
8656669 - A phase ii study of vp-16, intermediate-dose ara-c and carboplatin (vac) in advanced ac...
21905969 - Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic ...
12553679 - Long-term outcomes of acute myeloid leukemia in adults in pakistan.
21965779 - Efficacy of meloxicam in combination with preoperative chemotherapy for breast cancer -...
7539109 - A controlled study of recombinant human granulocyte colony-stimulating factor in elderl...
22184379 - Longitudinal assessment of chemotherapy-induced structural changes in cerebral white ma...
17159259 - Effect of low level helium-neon (he-ne) laser therapy in the prevention & treatment of ...
9584899 - Synovial sarcoma. evaluation of prognosis with emphasis on the study of dna ploidy and ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current oncology reports     Volume:  4     ISSN:  1523-3790     ISO Abbreviation:  Curr Oncol Rep     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-08-06     Completed Date:  2002-12-20     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  100888967     Medline TA:  Curr Oncol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  369-74     Citation Subset:  IM    
Affiliation:
Section of Developmental Therapeutics, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA. frankgiles@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adenine Nucleotides
Angiogenesis Inhibitors / therapeutic use
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Antimetabolites, Antineoplastic / therapeutic use
Antineoplastic Agents / therapeutic use*
Arabinonucleosides / therapeutic use
Azacitidine / analogs & derivatives*,  therapeutic use
Boronic Acids / therapeutic use
Cytosine / analogs & derivatives*,  therapeutic use
Dioxolanes / therapeutic use
Humans
Indoles / therapeutic use
Leukemia, Myeloid / drug therapy*,  pathology
Phthalazines / therapeutic use
Pyrazines / therapeutic use
Pyridines*
Pyrroles / therapeutic use
Thionucleotides / therapeutic use
Chemical
Reg. No./Substance:
0/Adenine Nucleotides; 0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents; 0/Arabinonucleosides; 0/Boronic Acids; 0/Dioxolanes; 0/Indoles; 0/Phthalazines; 0/Pyrazines; 0/Pyridines; 0/Pyrroles; 0/Thionucleotides; 0/bortezomib; 145918-75-8/troxacitabine; 2S9ZZM9Q9V/bevacizumab; 320-67-2/Azacitidine; 5DX9U76296/vatalanib; 71-30-7/Cytosine; 71IA9S35AJ/Semaxinib; 762RDY0Y2H/clofarabine; 776B62CQ27/decitabine; 85J5ZP6YSL/oblimersen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Brachial plexus injury after transfer of free latissimus dorsi musculocutaneous flap.
Next Document:  Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.